HOME
LEAP™ Advanced Therapy Platform
Accelerate Your Path to Clinic with BioCentriq’s LEAP™ Platform
The LEAP™ platform offered by BioCentriq provides early-stage biotech companies with novel cell therapy candidates an avenue to leverage proven expertise and assets to reach patients in record time.
Sponsors who leverage LEAP™ minimize up-front investment in process development, reduce risk, accelerate timelines, and lower the cost of IND-enabling studies and clinical production.
Benefits of Leveraging BioCentriq’s LEAP™ Platform
- Reduce process development and scale-up timelines by up to 75%
- De-risk clinical trials with proven manufacturing processes and analytical methods
- Move quickly by capitalizing on existing aseptic validation and facility and equipment qualifications
- Utilize pre-existing documentation including protocols, methods, reports and batch records
- Access a qualified team with verified experience and recognized expertise
Leverage BioCentriq Assets
Moving from project kick-off to patient dosing in six months is achieved using BioCentriq’s established methods and processes for scale up, including:
- Pre-Existing Master Batch Records
- Established SOPs
- Qualified Analytical Methods
- Trained Personnel
- Completed Aseptic Validation
- Proven and Reliable Supply Chain
- Phase Appropriate Quality System
- Fit-for-Purpose Facilities and Equipment
Why Choose BioCentriq?
- Experienced and expert team
- Pre-qualified equipment, methods and facilities
- Verified ability to scale-up
- Collaborative and transparent approach
- Willingness to integrate sponsor expertise either on-site or virtually
- Phase appropriate quality systems
- Track record of producing product for use in human clinical trials
"We're extremely enthusiastic about the promising results presented in our abstract, "Large-scale biomanufacturing platform to produce high-quality, therapeutically relevant NK cells using the LEAP-NK™ Platform." The results suggest BioCentriq’s LEAP-NK™ platform utilizing propriety feeder cell lines can enhance expansion of NK cells >12,000 fold."
Mary Loveras
Associate Director, MSAT
"At BioCentriq, we understand the complexities of navigating a funding-constrained environment, which is why we offer Rapid Tech Transfer, a risk-based approach to help therapy developers prioritize speed, reach milestones, and ultimately, get their therapeutics to patients in need."
Melissa Mastro
Senior MSAT Engineer
Related News
BioCentriq Expands Operations and Secures Cell Therapy Manufacturing Facility in Princeton, NJ
Watch Webinar On-Demand: The Role of Platform Processes in Cell Therapy
Four Legitimate Reasons to Prioritize Speed in Drug Therapy Development and How to Move Fast Safely
